Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company, develops pharmacological therapies to treat blinding diseases of the eye. It is developing suprachoroidal injection of CLS-TA, a proprietary preservative-free formulation of the corticosteroid triamcinolone acetonide, which is in Phase III clinical trial for the treatment of macular edema associated with non-infectious uveitis; suprachoroidal injection of CLS-TA and a concomitant intravitreal injection of Eylea, an inhibitor of vascular endothelial growth factor that is in Phase III clinical trial to treat macular edema associated with retinal vein occlusion; and suprachoroidal injection of CLS-TA alone or together with intravitreal injection of Eylea that is in phase II clinical trial for diabetic macular edema. The company also engages in the development of therapies in various areas, such as gene therapy for inherited retinal disorders, neovascular age-related macular degeneration, and other ocular diseases. The company was founded in 2011 and is headquartered in Alpharetta, Georgia.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CLSD
CUSIPN/A
Phone678-270-3631
Debt
Debt-to-Equity Ratio0.05
Current Ratio7.46
Quick Ratio7.46
Price-To-Earnings
Trailing P/E Ratio-4.55
Forward P/E Ratio-4.43
P/E GrowthN/A
Sales & Book Value
Annual Sales$340,000.00
Price / Sales995.15
Cash FlowN/A
Price / CashN/A
Book Value$0.84 per share
Price / Book12.61
Profitability
EPS (Most Recent Fiscal Year)($2.33)
Net Income$-58,970,000.00
Net Margins-17,094.20%
Return on Equity-131.37%
Return on Assets-97.24%
Miscellaneous
Employees34
Outstanding Shares31,950,000
Clearside Biomedical (NASDAQ:CLSD) Frequently Asked Questions
What is Clearside Biomedical's stock symbol?
Clearside Biomedical trades on the NASDAQ under the ticker symbol "CLSD."
How were Clearside Biomedical's earnings last quarter?
Clearside Biomedical Inc (NASDAQ:CLSD) posted its quarterly earnings results on Wednesday, May, 9th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by $0.05. Clearside Biomedical had a negative net margin of 17,094.20% and a negative return on equity of 131.37%. View Clearside Biomedical's Earnings History.
When is Clearside Biomedical's next earnings date?
What price target have analysts set for CLSD?
5 brokerages have issued 1-year price objectives for Clearside Biomedical's stock. Their forecasts range from $18.00 to $29.00. On average, they expect Clearside Biomedical's stock price to reach $23.50 in the next year. View Analyst Ratings for Clearside Biomedical.
Who are some of Clearside Biomedical's key competitors?
Some companies that are related to Clearside Biomedical include Lexicon Pharmaceuticals (LXRX), Deciphera Pharmaceuticals (DCPH), Impax Laboratories (IPXL), IMMURON Ltd/S (IMRN), ImmunoGen (IMGN), Uniqure (QURE), Theravance Biopharma (TBPH), Apellis Pharmaceuticals (APLS), Zai Lab (ZLAB), Alder Biopharmaceuticals (ALDR), Athenex (ATNX), Revance Therapeutics (RVNC), Retrophin (RTRX), Intra-Cellular Therapies (ITCI) and Eagle Pharmaceuticals (EGRX).
Who are Clearside Biomedical's key executives?
Clearside Biomedical's management team includes the folowing people:
- Mr. Daniel H. White, Founder, Pres, CEO & Director (Age 51)
- Mr. Charles A. Deignan, CFO & Sec. (Age 54)
- Dr. Glenn Noronha, Chief Scientific Officer (Age 53)
- Mr. Brion S. Raymond, Chief Commercial Officer (Age 48)
- Mr. Rafael V. Andino, VP of Engineering & Manufacturing (Age 53)
When did Clearside Biomedical IPO?
(CLSD) raised $50 million in an initial public offering (IPO) on Thursday, June 2nd 2016. The company issued 7,200,000 shares at $7.00 per share. Cowen and Company and Stifel served as the underwriters for the IPO and Needham & Company, Wedbush PacGrow was co-manager.
Has Clearside Biomedical been receiving favorable news coverage?
News coverage about CLSD stock has trended somewhat positive recently, according to Accern Sentiment. The research group identifies negative and positive press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Clearside Biomedical earned a news impact score of 0.18 on Accern's scale. They also assigned press coverage about the company an impact score of 45.35 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near term.
Who are Clearside Biomedical's major shareholders?
Clearside Biomedical's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Millennium Management LLC (4.37%), BlackRock Inc. (3.81%), Sphera Funds Management LTD. (3.23%), Rock Springs Capital Management LP (3.05%), Northern Trust Corp (0.76%) and Citadel Advisors LLC (0.56%). Company insiders that own Clearside Biomedical stock include Charles A Deignan, Christy L Shaffer, Clay Thorp, Daniel H White, Gerald D Cagle and Venture Advisors Iii Hatteras. View Institutional Ownership Trends for Clearside Biomedical.
Which institutional investors are buying Clearside Biomedical stock?
CLSD stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC, Sphera Funds Management LTD., BlackRock Inc., Citadel Advisors LLC, JPMorgan Chase & Co., EAM Global Investors LLC, Rock Springs Capital Management LP and Sofinnova Ventures Inc. Company insiders that have bought Clearside Biomedical stock in the last two years include Charles A Deignan, Christy L Shaffer, Daniel H White and Gerald D Cagle. View Insider Buying and Selling for Clearside Biomedical.
How do I buy shares of Clearside Biomedical?
Shares of CLSD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Clearside Biomedical's stock price today?
One share of CLSD stock can currently be purchased for approximately $10.59.
How big of a company is Clearside Biomedical?
Clearside Biomedical has a market capitalization of $341.83 million and generates $340,000.00 in revenue each year. The company earns $-58,970,000.00 in net income (profit) each year or ($2.33) on an earnings per share basis. Clearside Biomedical employs 34 workers across the globe.
How can I contact Clearside Biomedical?
Clearside Biomedical's mailing address is 900 NORTH POINT PARKWAY SUITE 200, ALPHARETTA GA, 30005. The company can be reached via phone at 678-270-3631 or via email at [email protected]
MarketBeat Community Rating for Clearside Biomedical (CLSD)
MarketBeat's community ratings are surveys of what our community members think about Clearside Biomedical and other stocks. Vote "Outperform" if you believe CLSD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLSD will underperform the S&P 500 over the long term. You may vote once every thirty days.
